Maximising Vision Outcomes in DME: Is Baseline VA Only One Piece of the Puzzle?

Dr. Varun Chaudhary highlights the importance of managing diabetic macular oedema (DME) with an emphasis on loading dose treatment for optimal vision outcomes. Patients with diabetes often fear vision loss, as it impacts independence and quality of life. A robust treatment approach ensures maximum vision gains and preservation of retinal anatomy. Evidence from VIVID, VISTA and Protocol T trials demonstrates that five loading doses of aflibercept yield significant and lasting improvements in vision. The key aspect of DME management, whether the aim is trying to recover vision or maintain the good vision that patients have, is to have an appropriate loading dose.